TY - JOUR
T1 - Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV
T2 - a review of recent research
AU - Cobb, Denise A.
AU - Smith, Nathan A.
AU - Edagwa, Benson J.
AU - McMillan, Jo Ellyn M.
N1 - Funding Information:
This paper was funded by the National Institutes of Health grant1R01AI145542-01A1 (B. Edagwa).
Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020
Y1 - 2020
N2 - Introduction: Despite significant advances in treatment and prevention of HIV-1 infection, poor adherence to daily combination antiretroviral therapy (ART) regimens remains a major obstacle toward achieving sustained viral suppression and prevention. Adherence to ART could also be compromised by adverse drug reactions and societal factors that limit access to therapy. Therefore, medicines that aim to improve adherence by limiting ART side effects, frequency of dosing and socially acceptable regimens are becoming more attractive. Areas covered: This review highlights recent advances and challenges in the development of long-acting drug delivery strategies for HIV prevention and treatment. Approaches for extended oral and transdermal deliveries, microbicides, broadly neutralizing antibodies, and long-acting implantable and injectable deliveries are reviewed. Expert opinion: Emerging approaches on long-acting antiretroviral therapies and broadly neutralizing antibody technologies are currently at various stages of development. Such efforts, if successful and become broadly accepted by clinicians and users, will provide newer and simpler options for prevention and treatment of HIV infection.
AB - Introduction: Despite significant advances in treatment and prevention of HIV-1 infection, poor adherence to daily combination antiretroviral therapy (ART) regimens remains a major obstacle toward achieving sustained viral suppression and prevention. Adherence to ART could also be compromised by adverse drug reactions and societal factors that limit access to therapy. Therefore, medicines that aim to improve adherence by limiting ART side effects, frequency of dosing and socially acceptable regimens are becoming more attractive. Areas covered: This review highlights recent advances and challenges in the development of long-acting drug delivery strategies for HIV prevention and treatment. Approaches for extended oral and transdermal deliveries, microbicides, broadly neutralizing antibodies, and long-acting implantable and injectable deliveries are reviewed. Expert opinion: Emerging approaches on long-acting antiretroviral therapies and broadly neutralizing antibody technologies are currently at various stages of development. Such efforts, if successful and become broadly accepted by clinicians and users, will provide newer and simpler options for prevention and treatment of HIV infection.
KW - HIV
KW - LASER ART
KW - broadly neutralizing antibodies
KW - injectables
KW - long-acting antiretrovirals
KW - microbicides
KW - subcutaneous implants
KW - transdermal delivery
UR - http://www.scopus.com/inward/record.url?scp=85087767666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087767666&partnerID=8YFLogxK
U2 - 10.1080/17425247.2020.1783233
DO - 10.1080/17425247.2020.1783233
M3 - Review article
C2 - 32552187
AN - SCOPUS:85087767666
SN - 1742-5247
SP - 1227
EP - 1238
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
ER -